HC Wainwright Has Bullish Estimate for RAPT FY2024 Earnings

RAPT Therapeutics, Inc. (NASDAQ:RAPT) – Stock analysts at HC Wainwright increased their FY2024 EPS estimates for RAPT Therapeutics in a research note issued to investors on Monday, November 25th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($2.56) per share for the year, up from their prior estimate of ($2.70). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for RAPT Therapeutics’ current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for RAPT Therapeutics’ Q4 2024 earnings at ($0.58) EPS, Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.63) EPS and FY2025 earnings at ($2.61) EPS.

Several other research analysts have also recently commented on RAPT. JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Piper Sandler lowered shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $8.00 to $2.00 in a research report on Monday, November 11th. Stifel Nicolaus reaffirmed a “hold” rating and set a $2.00 price objective (down from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th. Wells Fargo & Company dropped their target price on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. Finally, UBS Group decreased their price target on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research note on Monday, September 9th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $9.50.

RAPT Therapeutics Stock Up 9.8 %

RAPT Therapeutics stock opened at $1.23 on Wednesday. RAPT Therapeutics has a 12 month low of $1.00 and a 12 month high of $27.35. The stock has a market cap of $43.00 million, a price-to-earnings ratio of -0.44 and a beta of 0.33. The business has a 50 day moving average price of $1.80 and a two-hundred day moving average price of $2.61.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.09.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Readystate Asset Management LP acquired a new stake in shares of RAPT Therapeutics in the 3rd quarter valued at $36,000. Barclays PLC raised its position in shares of RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after acquiring an additional 29,195 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of RAPT Therapeutics in the 1st quarter valued at $97,000. XTX Topco Ltd bought a new position in shares of RAPT Therapeutics in the 2nd quarter worth $108,000. Finally, Hennion & Walsh Asset Management Inc. grew its stake in shares of RAPT Therapeutics by 8.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock worth $148,000 after purchasing an additional 3,824 shares during the period. Institutional investors and hedge funds own 99.09% of the company’s stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.